Patent ID: 8580520

Claim:
A method for determining a therapy for a gastrointestinal cancer expressing wild type KRAS in a subject, said method comprising: i) determining the level of YKL-40 in a blood, serum, or plasma sample obtained from the subject; and ii) comparing said level of YKL-40 with a reference level of YKL-40 obtained in healthy individuals selected from the following set of age dependent cut-off values defined as the 90 th percentile: natural log (ln)(plasma YKL-40 μg/l)=3.5+0.02×age of the subject (years); the 95 th percentile: ln(plasma YKL-40 μg/l)=3.6+0.02×age of the subject (years); and the 97.5 th percentile: ln(plasma YKL-40 μg/l)=3.9+0.02×age of the subject (years); and iii) treating said subject with an EGFR inhibitor when the determined level of YKL-40 is below the reference level.